Evidence map›Paper›PMID 41445566›Full record

ReviewBladder cancer (Amsterdam, Netherlands)

Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization.

Timothy Hanlon, Vincent D D'Andrea, Isabella Stelter, Raie Bekele, Yuzhen Zhou, Kent W Mouw

Abstract readReview
In one paragraph

Review in Bladder cancer (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Timothy HanlonDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID https://orcid.org/0000-0003-0676-942X
Vincent D D'AndreaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Isabella StelterDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Raie BekeleDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yuzhen ZhouDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kent W MouwDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder CancerR01CA279221 · NCI · DANA-FARBER CANCER INST · PI Kent W Mouw, Eliezer M Van Allen · 2024 to 2026
$2.2M
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder CancerR01CA272657 · NCI · DANA-FARBER CANCER INST · PI MOUW, KENT W · 2022 to 2025
$2.1M
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder CancerR01CA289304 · NCI · DANA-FARBER CANCER INST · PI Kent W Mouw · 2024 to 2026
$1.5M
Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder CancerR21CA288234 · NCI · DANA-FARBER CANCER INST · PI MOUW, KENT W · 2024 to 2025
$453k
NCI NIH HHS R01 CA272657NCI NIH HHS R01 CA279221NCI NIH HHS R01 CA289304NCI NIH HHS R21 CA288234
6 · The paper itself

Abstract

Background: Objective: We systematically collected data from published studies that have utilized orthotopic bladder tumor models in mice or rats to identify trends and outcomes across techniques. We used these data to optimize a surgical orthotopic technique. Methods: A PubMed search was performed to identify articles involving orthotopic implantation of tumor cells into mouse or rat bladders for research purposes. Results were individually reviewed and filtered. All studies reporting preclinical models established via a surgical, transurethral, and/or ultrasound-guided approach were included. Surgical orthotopic tumor implantation experiments were performed and data collected. Results: A total of 254 studies were identified, of which 187 met criteria and were included in the analysis. Data regarding each orthotopic technique was reviewed and trends were identified. Transurethral installation was the most commonly used method but had the lowest tumor take rate. The surgical approach had the highest metastatic rate. These data were used to inform optimization of the surgical orthotopic approach in our laboratory. The study is limited by its retrospective design and heterogeneity of data reporting across studies. Conclusions: Tumor take rates vary across orthotopic implantation techniques. Optimization of a surgical implantation approach is feasible. These findings can inform best practices for orthotopic bladder cancer models.

Indexed as

animal modelsbladder cancerdrug developmentmuscle-invasive bladder cancer

Identifiers

PMID41445566
PMCPMC12722681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.